Affinage

AGTRAP

Type-1 angiotensin II receptor-associated protein · UniProt Q6RW13

Length
159 aa
Mass
17.4 kDa
Annotated
2026-06-09
39 papers in source corpus 21 papers cited in narrative 21 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

AGTRAP (ATRAP) is a multi-pass transmembrane protein that functions as a negative regulator of angiotensin II type 1 receptor (AT1R) signaling, binding specifically to the carboxyl-terminal cytoplasmic tail of the AT1a receptor and not to other G-protein-coupled receptors (PMID:10358057, PMID:12960423). It localizes to the plasma membrane and to intracellular trafficking vesicles (ER, Golgi, endocytic vesicles), with constitutive translocation toward the plasma membrane; its cytoplasmic C-terminal domain is required for AT1R binding (PMID:12960423). Through this interaction ATRAP promotes AT1R internalization and surface downregulation, thereby suppressing downstream AT1R-mediated signaling including phospholipase C activation, p38 MAPK, STAT3, and Akt, and attenuating angiotensin II-induced proliferative and hypertrophic responses in vascular smooth muscle cells and cardiomyocytes (PMID:10358057, PMID:11162453, PMID:15757644). Genetic deletion in mice establishes ATRAP as a physiological negative regulator: Atrap-deficient animals show elevated blood pressure, increased plasma volume, and enhanced renal AT1R surface expression (PMID:20093357), and additionally develop high-fat-diet-driven metabolic dysfunction that is rescued by transplantation of ATRAP-overexpressing adipose tissue (PMID:23902639). Beyond AT1R, ATRAP interacts with the cardiac sarcoplasmic reticulum Ca2+-ATPase SERCA2a and enhances SERCA-dependent Ca2+ uptake to facilitate ventricular relaxation (PMID:27015675). ATRAP abundance is tightly controlled post-translationally by proteasomal and immunoproteasomal degradation—notably via the immunoproteasome subunit β5i (PSMB8), whose action de-represses AT1R-driven NF-κB, NADPH oxidase, and TGF-β1/Smad signaling (PMID:25526681, PMID:30571551)—and post-transcriptionally by miR-125a/b-5p and miR-34a (PMID:37981211, PMID:41291382). In cancer, ATRAP operates independently of AT1R, driving a USP14/PBX3/AKT-mTOR axis in breast cancer (PMID:35414770) and an IL-6/JAK2/STAT3 pathway in glioma (PMID:41689202).

Mechanistic history

Synthesis pass · year-by-year structured walk · 20 steps
  1. 1999 High

    Established that ATRAP is a dedicated AT1R-interacting partner, answering whether a receptor-specific regulator of angiotensin signaling exists.

    Evidence Yeast two-hybrid, affinity chromatography, Co-IP, and PLC functional assay in COS-7 cells showing selective binding to the AT1a C-terminal tail

    PMID:10358057

    Open questions at the time
    • Did not define topology or trafficking
    • Mechanism of PLC inhibition not resolved beyond binding
  2. 2000 Medium

    Showed ATRAP acts by promoting AT1R internalization and suppressing growth signaling, framing it as a functional negative regulator rather than a passive binder.

    Evidence Overexpression in adult VSMCs with receptor internalization, DNA synthesis, and STAT3/Akt phosphorylation readouts

    PMID:11162453

    Open questions at the time
    • Overexpression only, no loss-of-function
    • Internalization machinery linking ATRAP to AT1R not identified
  3. 2002 High

    Identified RACK1 as an ATRAP partner, expanding the interactome beyond AT1R toward a possible scaffolding role.

    Evidence Yeast two-hybrid, GST pull-down, Co-IP, and surface plasmon resonance

    PMID:11733189

    Open questions at the time
    • Functional consequence of RACK1 binding not defined
    • Not linked to AT1R regulation
  4. 2003 High

    Defined ATRAP membrane topology, trafficking behavior, and the C-terminal domain as the AT1R-binding determinant, establishing the structural basis for its regulatory function.

    Evidence Epitope-tag topology mapping, EM, immunofluorescence, real-time vesicle tracking, and deletion-mutant reporter/proliferation assays

    PMID:12960423

    Open questions at the time
    • Structure of the AT1R-ATRAP interface not solved
    • How vesicular ATRAP couples to AT1R endocytosis unresolved
  5. 2005 Medium

    Extended the negative-regulator model to cardiac hypertrophy, showing ATRAP reduces surface AT1R and dampens p38 MAPK-driven hypertrophic responses.

    Evidence Overexpression in cardiomyocytes with surface receptor binding, p38 phosphorylation, c-fos reporter, and protein synthesis assays

    PMID:15757644

    Open questions at the time
    • Overexpression-based; in vivo cardiac role not yet tested
    • Single lab
  6. 2006 Medium

    Demonstrated in vivo ATRAP/AT1R colocalization along the nephron and salt-responsive co-regulation, implicating ATRAP in renal angiotensin physiology.

    Evidence In situ hybridization, Western blot, immunohistochemistry, and dietary salt manipulation in kidney

    PMID:16514431

    Open questions at the time
    • Correlative; no causal manipulation
    • Functional consequence for blood pressure untested at this stage
  7. 2010 High

    Provided definitive genetic proof that ATRAP negatively regulates renal AT1R and blood pressure in vivo.

    Evidence Atrap-/- mice with telemetry, plasma volume, 125I-Ang II binding, and proximal tubular function assays

    PMID:20093357

    Open questions at the time
    • Whole-body knockout; tissue-specific contribution not isolated
    • Did not address non-renal phenotypes
  8. 2011 Medium

    Identified ATRAP as the membrane anchor that recruits the phospholipid transfer protein RdgBβ (PITPNC1), suggesting a lipid-signaling-linked role.

    Evidence Co-IP and PMA-induced membrane recruitment assay in COS-7 cells

    PMID:21728994

    Open questions at the time
    • Physiological significance of RdgBβ recruitment unknown
    • Not connected to AT1R pathway
  9. 2013 High

    Revealed an AT1R-related metabolic protective function of adipose ATRAP through knockout plus rescue transplantation.

    Evidence Agtrap-/- mice on high-fat diet with fat-pad transplantation from ATRAP-transgenic donors and metabolic phenotyping

    PMID:23902639

    Open questions at the time
    • Molecular mediators in adipocytes not fully defined
    • Whether effect is strictly AT1R-dependent unresolved
  10. 2014 Medium

    Established that proteasomal turnover of ATRAP is a control point governing AT1R signaling output during hypertrophy.

    Evidence Ang II infusion mouse model with bortezomib treatment and p38/STAT3 pathway readouts

    PMID:25526681

    Open questions at the time
    • Specific E3 ligase not identified here
    • Pharmacological inhibitor lacks proteasome-target specificity
  11. 2016 High

    Discovered a non-AT1R molecular function: ATRAP binds and stimulates SERCA2a to facilitate ventricular relaxation.

    Evidence Pull-down/MALDI-MS, Co-IP, SPR, SR Ca2+ uptake assay, cardiomyocyte Ca2+ transient measurements, and echocardiography in Atrap-/- mice

    PMID:27015675

    Open questions at the time
    • Structural basis of SERCA2a stimulation not resolved
    • Interplay between AT1R and SERCA2a functions unclear
  12. 2019 High

    Identified the immunoproteasome subunit β5i (PSMB8) as the specific degrader of ATRAP, linking ATRAP turnover to atrial fibrillation via NF-κB/NADPH oxidase/TGF-β1 signaling.

    Evidence β5i KO mice, AAV9-β5i and AAV9-ATRAP overexpression, atrial electrophysiology, NADPH oxidase activity, and pathway Western blots

    PMID:30571551

    Open questions at the time
    • Direct β5i-ATRAP cleavage not biochemically reconstituted
    • Ubiquitination requirement for degradation not detailed
  13. 2019 Medium

    Refined the tissue locus of ATRAP's blood-pressure role, showing proximal tubule ATRAP is dispensable for angiotensin-dependent hypertension.

    Evidence Pepck-Cre proximal tubule-specific ATRAP KO with tail-cuff and radiotelemetric BP under Ang II infusion

    PMID:30977419

    Open questions at the time
    • Does not identify which nephron segment or tissue mediates the whole-body phenotype
    • Negative result limited to the Ang II infusion model
  14. 2021 Medium

    Defined post-transcriptional control of ATRAP via HuR-mediated mRNA shuttling regulated by SAM methylation in fatty liver disease.

    Evidence HuR methylation assay, HuR-ATRAP RNA immunoprecipitation, nucleocytoplasmic fractionation, and SAM supplementation in HFD rats and L02 cells

    PMID:33753727

    Open questions at the time
    • Downstream functional consequence of ATRAP induction in NAFLD not fully mapped
    • Single lab
  15. 2022 Medium

    Uncovered an AT1R-independent oncogenic function of ATRAP in breast cancer through a USP14/PBX3/AKT-mTOR axis with USF1 as its upstream transcriptional regulator.

    Evidence Co-IP, microarray pathway analysis, siRNA/overexpression functional assays, and rescue experiments

    PMID:35414770

    Open questions at the time
    • USP14-mediated deubiquitination inferred, not reconstituted
    • Mechanism of ATRAP-USP14 coupling unclear
  16. 2022 Medium

    Showed ATRAP stability is preserved by DJ-1 inhibition of proteasome subunit PSMB10, adding a regulatory route protecting AT1R signaling suppression.

    Evidence Quantitative proteomics, DJ-1/PSMB10 Co-IP, proteasome and ubiquitination assays, cardiomyocyte assays, and TAC mouse model

    PMID:36509316

    Open questions at the time
    • Direct PSMB10-ATRAP targeting not isolated from indirect effects
    • Single lab
  17. 2022 Medium

    Connected tubular ATRAP-AT1R signaling to immune crosstalk, showing it regulates M2 macrophage accumulation affecting glomerular injury in diabetic nephropathy.

    Evidence Streptozotocin-diabetic ATRAP-KO and proximal-tubule knockdown mice with adoptive M2 macrophage transfer and CD206 immunohistochemistry

    PMID:35240129

    Open questions at the time
    • Molecular signal linking tubular ATRAP to macrophage polarization undefined
    • Single lab
  18. 2023 Medium

    Identified miR-125a-5p/miR-125b-5p as direct repressors of ATRAP, defining a microRNA layer tuning AT1R signaling in distal tubule cells.

    Evidence Luciferase reporter of miRNA-ATRAP 3'UTR binding and miRNA inhibitor treatment with AT1R signaling readouts in DCT cells

    PMID:37981211

    Open questions at the time
    • In vivo physiological impact of these miRNAs on ATRAP not established
    • Single lab
  19. 2025 Medium

    Established a miR-34a-AGTRAP negative feedback loop driving vascular smooth muscle inflammation and linking ATRAP to vascular aging.

    Evidence miR-34a overexpression and luciferase 3'UTR targeting in HASMC, AGTRAP forced-expression rescue, and aging primate/rodent tissue analysis

    PMID:41291382

    Open questions at the time
    • Causal contribution to vascular aging in vivo not proven
    • Relationship between AGTRAP/SIRT1 co-regulation mechanistically unclear
  20. 2026 Medium

    Demonstrated an AT1R-independent pro-tumor role in glioma, placing AGTRAP upstream of IL-6/JAK2/STAT3 signaling.

    Evidence shRNA knockdown in A172/U251 cells, proliferation/apoptosis assays, IL-6 measurement, JAK2/STAT3 phosphorylation, recombinant IL-6 rescue, and orthotopic xenograft

    PMID:41689202

    Open questions at the time
    • How AGTRAP controls IL-6 expression molecularly is undefined
    • Single lab

Open questions

Synthesis pass · forward-looking unresolved questions
  • How a single transmembrane protein integrates its AT1R-internalization function, SERCA2a Ca2+ regulation, lipid-transfer recruitment, and AT1R-independent oncogenic signaling into a unified mechanism remains unresolved.
  • No structural model of ATRAP or its complexes
  • Mechanism switching ATRAP between cardiovascular regulator and cancer effector unknown
  • Whether oncogenic functions require its membrane topology untested

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 5 GO:0060089 molecular transducer activity 2
Localization
GO:0005783 endoplasmic reticulum 1 GO:0005794 Golgi apparatus 1 GO:0005886 plasma membrane 1 GO:0031410 cytoplasmic vesicle 1
Pathway
R-HSA-162582 Signal Transduction 4 R-HSA-392499 Metabolism of proteins 3 R-HSA-9609507 Protein localization 2
Partners
AGTR1ATP2A2PBX3PITPNC1PSMB10PSMB8RACK1USP14

Evidence

Reading pass · 21 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1999 ATRAP (AGTRAP) was identified as a novel protein that specifically interacts with the carboxyl-terminal cytoplasmic domain of the AT1a receptor but not with AT2, m3 muscarinic, bradykinin B2, endothelin B, or beta2-adrenergic receptors. Overexpression of ATRAP in COS-7 cells markedly inhibited AT1a receptor-mediated activation of phospholipase C without affecting m3 receptor-mediated activation. Yeast two-hybrid screen, affinity chromatography, co-immunoprecipitation, fluorescence microscopy colocalization, functional PLC activation assay The Journal of biological chemistry High 10358057
2000 Overexpression of ATRAP potentiated AT1 receptor internalization upon angiotensin II stimulation in vascular smooth muscle cells (VSMCs) and inhibited AT1 receptor-induced DNA synthesis, associated with inhibition of STAT3 and Akt phosphorylation. Transfection/overexpression in adult VSMCs, receptor internalization assay, DNA synthesis assay, Western blot for STAT3 and Akt phosphorylation Biochemical and biophysical research communications Medium 11162453
2002 Human AGTRAP protein interacts with RACK1 (Receptor of Activated Protein C Kinase), as identified by yeast two-hybrid screening and confirmed by GST pull-down, co-immunoprecipitation, and surface plasmon resonance. Yeast two-hybrid, GST pull-down, co-immunoprecipitation, surface plasmon resonance The international journal of biochemistry & cell biology High 11733189
2003 ATRAP is a transmembrane protein with three N-terminal hydrophobic domains (residues 14-36, 55-77, 88-108) and a hydrophilic C-terminal cytoplasmic tail (residues 109-161). Its N-terminus faces extracellularly, it localizes to intracellular trafficking vesicles (ER, Golgi, endocytic vesicles) and plasma membrane with constitutive translocation toward the plasma membrane. Deletion of the C-terminal domain abolishes AT1 receptor binding and causes perinuclear vesicle clustering. ATRAP overexpression decreases inositol lipid generation, suppresses angiotensin II-stimulated c-fos promoter activity, and decreases cell proliferation. Epitope-tagged constructs for topology determination, electron microscopy, immunofluorescence colocalization, real-time vesicle tracking, deletion mutant analysis, reporter gene assay, cell proliferation assay Molecular biology of the cell High 12960423
2005 Overexpression of ATRAP significantly decreases the number of AT1 receptors on the surface of cardiomyocytes, decreases p38 MAPK phosphorylation, reduces c-fos promoter activity, and decreases protein synthesis upon angiotensin II treatment, indicating ATRAP promotes AT1R downregulation and attenuates hypertrophic responses. Overexpression in cardiomyocytes, surface receptor binding assay, Western blot for p38 phosphorylation, reporter gene assay, protein synthesis measurement FEBS letters Medium 15757644
2006 ATRAP protein colocalizes with AT1 receptor in renal tubular cells in vivo, distributed along nephron segments from Bowman's capsules to inner medullary collecting ducts. Dietary salt depletion significantly decreased renal expression of both ATRAP and AT1 receptor. In situ hybridization, Western blot, immunohistochemistry, dietary salt manipulation Kidney international Medium 16514431
2008 ATRAP is expressed in differentiated brown and white adipocytes; beta3-adrenergic stimulation suppresses ATRAP expression through JAK2/STAT signaling, as inhibition of PKA and JAK2 reversed the beta3-adrenergic suppression of ATRAP expression. Adipocyte differentiation and stimulation assays, Western blot for STAT1/STAT3 phosphorylation, pharmacological inhibitors of PKA and JAK2 Hormone and metabolic research Medium 18236361
2010 Atrap-deficient (Atrap-/-) mice show increased arterial blood pressure, increased plasma volume, lower plasma renin concentration, and enhanced surface expression of AT1 receptors in the renal cortex with increased carboanhydrase-sensitive proximal tubular function, demonstrating that Atrap acts as a negative regulator of AT1 receptors in renal tubules in vivo. Atrap-/- mouse generation, blood pressure telemetry, plasma volume measurement, 125I-angiotensin II binding assay, renal cortex fractionation, carboanhydrase-sensitive proximal tubular function assay Journal of the American Society of Nephrology High 20093357
2011 The PITP domain of RdgBβ (PITPNC1) interacts with ATRAP (AGTRAP), an integral membrane protein. Upon PMA treatment, RdgBβ is recruited to membranes via its PITP domain through interaction with ATRAP. Co-immunoprecipitation, PMA stimulation, membrane recruitment assay in COS-7 cells The Biochemical journal Medium 21728994
2013 Agtrap-/- mice under high-fat dietary loading develop systemic metabolic dysfunction including increased fat accumulation, hypertension, dyslipidemia, insulin resistance, and adipose tissue inflammation. Subcutaneous transplantation of fat pads overexpressing ATRAP (from transgenic mice) to Agtrap-/- mice improved the systemic metabolic dysfunction, demonstrating a protective role of adipose ATRAP against insulin resistance. Agtrap-/- mouse generation, high-fat diet challenge, fat pad transplantation from ATRAP transgenic donors, metabolic phenotyping Journal of the American Heart Association High 23902639
2014 Proteasomal degradation of ATRAP occurs during angiotensin II-induced cardiac hypertrophy; proteasome inhibitor bortezomib blocked ATRAP degradation and attenuated AT1R-mediated p38 MAPK and STAT3 signaling pathways, thereby reducing cardiac hypertrophy, fibrosis, and inflammation. Ang II infusion mouse model, bortezomib treatment, Western blot for proteasome activity, ATRAP protein levels, p38 MAPK and STAT3 phosphorylation Journal of molecular and cellular cardiology Medium 25526681
2016 ATRAP interacts with the cardiac Ca2+-ATPase SERCA2a, confirmed by pull-down (MALDI-MS), co-immunoprecipitation, and surface plasmon resonance. ATRAP enhances SERCA-dependent Ca2+ uptake in isolated SR membrane vesicles. Atrap-/- myocytes show prolonged Ca2+ transient decay and sarcomere re-lengthening, and Atrap-/- mice have decreased maximum ventricular filling rate, indicating ATRAP facilitates ventricular relaxation via SERCA2a stimulation. Pull-down with MALDI-MS sequencing, co-immunoprecipitation, surface plasmon resonance, Ca2+ uptake assay in SR vesicles, cardiomyocyte sarcomere shortening and Ca2+ transient measurements, echocardiography in Atrap-/- mice Cardiovascular research High 27015675
2019 Immunoproteasome subunit β5i (PSMB8) directly targets ATRAP for degradation. β5i knockout attenuated Ang II-induced atrial fibrillation, fibrosis, and oxidative stress, while restoring ATRAP levels. Overexpression of ATRAP abrogated Ang II-induced atrial remodeling and AF in β5i-overexpressing mice. Mechanistically, β5i-mediated ATRAP degradation leads to activation of AT1R-mediated NF-κB signaling, increased NADPH oxidase activity, and TGF-β1/Smad signaling. β5i KO mice, recombinant AAV9-β5i injection, AAV9-ATRAP overexpression, atrial electrophysiology (telemetry), Western blot, NADPH oxidase activity assay Hypertension High 30571551
2019 Proximal tubule-specific ATRAP knockout (PT-KO) mice showed no significant difference in blood pressure at baseline or in pressor response to angiotensin II infusion compared to wild-type mice, indicating that ATRAP in renal proximal tubules has a minor role in angiotensin-dependent hypertension in vivo. Cre/loxP proximal tubule-specific ATRAP KO using Pepck-Cre, tail-cuff and radiotelemetric blood pressure measurement, angiotensin II infusion, laser-capture microdissection and immunohistochemistry Journal of the American Heart Association Medium 30977419
2021 SAM (S-adenosylmethionine) upregulates ATRAP protein expression in NAFLD by methylating HuR protein, which controls HuR subcellular localization; HuR directly binds ATRAP mRNA and controls its nucleocytoplasmic shuttling for export from the nucleus, thereby regulating ATRAP translation. HuR methylation assay, RNA immunoprecipitation (HuR-ATRAP mRNA binding), nucleocytoplasmic fractionation, SAM supplementation in high-fat diet rats and oleic acid-treated L02 cells Cell death & disease Medium 33753727
2022 In breast cancer cells, ATRAP directs USP14 (Ubiquitin-specific protease 14)-mediated deubiquitination and stabilization of PBX3 (Pre-B cell leukemia homeobox 3), and promotes AKT/mTOR signaling pathway activation; ATRAP is itself a transcriptional target of USF1 (Upstream stimulatory factor 1). Co-immunoprecipitation, microarray pathway analysis, siRNA knockdown, overexpression functional assays (proliferation, metastasis, glycolysis), rescue experiments International journal of biological sciences Medium 35414770
2022 DJ-1 (PARK7) in hypoxia-conditioned MSC-derived extracellular vesicles suppresses cardiac hypertrophy by directly physically interacting with and inhibiting proteasome subunit PSMB10 activity, which in turn reduces ubiquitination-mediated degradation of ATRAP, thereby preserving AT1R-mediated signaling inhibition. Quantitative proteomics, co-immunoprecipitation (DJ-1/PSMB10), proteasome activity assay, ubiquitination assay for ATRAP, neonatal rat cardiomyocyte assays, TAC mouse model Pharmacological research Medium 36509316
2022 Tubular ATRAP-mediated modulation of AT1R signaling regulates the accumulation of tubulointerstitial M2-polarized macrophages (marked by CD206), thereby affecting glomerular injury in diabetic nephropathy via tubule-glomerular crosstalk. Adoptive transfer of M2 macrophages into diabetic ATRAP-knockout mice ameliorated glomerular injury. Streptozotocin-induced diabetic ATRAP-KO mice, proximal tubule-specific ATRAP knockdown mice, adoptive macrophage transfer, immunohistochemistry for CD206, renal mRNA analysis for TNF-α and oxidative stress markers Kidney international Medium 35240129
2023 miR-125a-5p and miR-125b-5p directly repress ATRAP/Atrap mRNA expression. Inhibition of miR-125a-5p/miR-125b-5p suppresses Ang II-AT1R signaling in mouse distal convoluted tubule cells by increasing ATRAP levels. miRNA target prediction, luciferase reporter assay for direct miRNA-ATRAP 3'UTR interaction, miRNA inhibitor treatment in mouse distal convoluted tubule cells, AT1R signaling readouts The Journal of biological chemistry Medium 37981211
2025 miR-34a directly targets AGTRAP mRNA in human aortic smooth muscle cells (HASMC); Ang II upregulates miR-34a, which suppresses AGTRAP and SIRT1 expression; forced AGTRAP expression rescues miR-34a-induced pro-inflammatory gene upregulation (IL-6, COX2, MCP-1, MFGE8), establishing a negative feedback loop where AGTRAP downmodulation further enhances miR-34a expression. miR-34a overexpression in HASMC, luciferase reporter assay confirming direct miR-34a targeting of AGTRAP 3'UTR, AGTRAP forced expression rescue, Ang II stimulation, aging primate/rodent tissue analysis GeroScience Medium 41291382
2026 AGTRAP knockdown in glioma cells suppressed proliferation, increased apoptosis, reduced IL-6 mRNA and protein levels, and attenuated JAK2/STAT3 activation; recombinant IL-6 partially restored JAK2/STAT3 signaling and mitigated growth inhibition caused by AGTRAP silencing, placing AGTRAP upstream of IL-6/JAK2/STAT3 in glioma. shRNA knockdown in A172 and U251 glioma cells, proliferation and apoptosis assays, IL-6 ELISA/Western blot, JAK2/STAT3 phosphorylation assay, recombinant IL-6 rescue, orthotopic xenograft model CNS neuroscience & therapeutics Medium 41689202

Source papers

Stage 0 corpus · 39 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1999 Cloning and characterization of ATRAP, a novel protein that interacts with the angiotensin II type 1 receptor. The Journal of biological chemistry 145 10358057
2003 The angiotensin II type I receptor-associated protein, ATRAP, is a transmembrane protein and a modulator of angiotensin II signaling. Molecular biology of the cell 99 12960423
2005 The novel angiotensin II type 1 receptor (AT1R)-associated protein ATRAP downregulates AT1R and ameliorates cardiomyocyte hypertrophy. FEBS letters 75 15757644
2000 ATRAP, novel AT1 receptor associated protein, enhances internalization of AT1 receptor and inhibits vascular smooth muscle cell growth. Biochemical and biophysical research communications 67 11162453
1999 RET: a poly A-trap retrovirus vector for reversible disruption and expression monitoring of genes in living cells. Nucleic acids research 64 10572187
2006 Interacting molecule of AT1 receptor, ATRAP, is colocalized with AT1 receptor in the mouse renal tubules. Kidney international 56 16514431
2019 Immunoproteasome Subunit β5i Promotes Ang II (Angiotensin II)-Induced Atrial Fibrillation by Targeting ATRAP (Ang II Type I Receptor-Associated Protein) Degradation in Mice. Hypertension (Dallas, Tex. : 1979) 55 30571551
2014 Activation of the cardiac proteasome promotes angiotension II-induced hypertrophy by down-regulation of ATRAP. Journal of molecular and cellular cardiology 55 25526681
2010 Atrap deficiency increases arterial blood pressure and plasma volume. Journal of the American Society of Nephrology : JASN 43 20093357
2013 Angiotensin receptor-binding protein ATRAP/Agtrap inhibits metabolic dysfunction with visceral obesity. Journal of the American Heart Association 38 23902639
2013 The physiology and pathophysiology of a novel angiotensin receptor-binding protein ATRAP/Agtrap. Current pharmaceutical design 34 23176217
2002 Identification and characterization of AGTRAP, a human homolog of murine Angiotensin II Receptor-Associated Protein (Agtrap). The international journal of biochemistry & cell biology 31 11733189
2019 Ablation of Immunoproteasome β5i Subunit Suppresses Hypertensive Retinopathy by Blocking ATRAP Degradation in Mice. Molecular therapy : the journal of the American Society of Gene Therapy 30 31636038
2022 Extracellular vesicles DJ-1 derived from hypoxia-conditioned hMSCs alleviate cardiac hypertrophy by suppressing mitochondria dysfunction and preventing ATRAP degradation. Pharmacological research 27 36509316
2011 The phosphatidylinositol transfer protein RdgBβ binds 14-3-3 via its unstructured C-terminus, whereas its lipid-binding domain interacts with the integral membrane protein ATRAP (angiotensin II type I receptor-associated protein). The Biochemical journal 27 21728994
2021 S-adenosylmethionine upregulates the angiotensin receptor-binding protein ATRAP via the methylation of HuR in NAFLD. Cell death & disease 26 33753727
2022 Deficiency of the kidney tubular angiotensin II type1 receptor-associated protein ATRAP exacerbates streptozotocin-induced diabetic glomerular injury via reducing protective macrophage polarization. Kidney international 23 35240129
2022 USF1-ATRAP-PBX3 Axis Promote Breast Cancer Glycolysis and Malignant Phenotype by Activating AKT/mTOR Signaling. International journal of biological sciences 23 35414770
2011 Prepubertal angiotensin blockade exerts long-term therapeutic effect through sustained ATRAP activation in salt-sensitive hypertensive rats. Journal of hypertension 23 21844822
2021 ATRAP, a receptor-interacting modulator of kidney physiology, as a novel player in blood pressure and beyond. Hypertension research : official journal of the Japanese Society of Hypertension 21 34642449
2017 Effect of prehypertensive losartan therapy on AT1R and ATRAP methylation of adipose tissue in the later life of high‑fat‑fed spontaneously hypertensive rats. Molecular medicine reports 17 29257219
2017 Silencing of AtRAP, a target gene of a bacteria-induced small RNA, triggers antibacterial defense responses through activation of LSU2 and down-regulation of GLK1. The New phytologist 14 28656601
2015 Angiotensin II Type 1 Receptor Binding Molecule ATRAP as a Possible Modulator of Renal Sodium Handling and Blood Pressure in Pathophysiology. Current medicinal chemistry 14 26295465
2016 The angiotensin receptor-associated protein Atrap is a stimulator of the cardiac Ca2+-ATPase SERCA2a. Cardiovascular research 12 27015675
2019 Effects of ATRAP in Renal Proximal Tubules on Angiotensin-Dependent Hypertension. Journal of the American Heart Association 11 30977419
2017 ATRAP Expression in Brown Adipose Tissue Does Not Influence the Development of Diet-Induced Metabolic Disorders in Mice. International journal of molecular sciences 10 28335584
2012 14-3-3 protein and ATRAP bind to the soluble class IIB phosphatidylinositol transfer protein RdgBβ at distinct sites. Biochemical Society transactions 10 22435829
2022 Melatonin inhibits angiotensin II-induced atrial fibrillation through preventing degradation of Ang II Type I Receptor-Associated Protein (ATRAP). Biochemical pharmacology 9 35710020
2023 miR-125a-5p/miR-125b-5p contributes to pathological activation of angiotensin II-AT1R in mouse distal convoluted tubule cells by the suppression of Atrap. The Journal of biological chemistry 8 37981211
2021 Construction and Comprehensive Analysis of a Stratification System Based on AGTRAP in Patients with Hepatocellular Carcinoma. Disease markers 6 34840632
2008 Expression of ATRAP in adipocytes and negative regulation by beta-adrenergic stimulation of JAK/STAT. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 6 18236361
2022 Modulation of blood pressure regulatory genes in the Agtrap-Plod1 locus associated with a deletion in Clcn6. Physiological reports 4 35927940
2016 Hypomethylation of Agtrap is associated with long-term inhibition of left ventricular hypertrophy in prehypertensive losartan-treated spontaneously hypertensive rats. Molecular medicine reports 4 28000857
2026 Angiotensin II Receptor-Associated Protein (AGTRAP) Enhances Glioma Cell Survival Through the IL-6/JAK2/STAT3 Pathway and Correlates With an Immunosuppressive Microenvironment. CNS neuroscience & therapeutics 1 41689202
2012 [Physiology of novel AT1 receptor-binding molecule, ATRAP]. Nihon rinsho. Japanese journal of clinical medicine 1 23012794
2026 AGTRAP mediates exosome-driven communication between cancer cells and macrophages via p38 MAPK pathway to promote hepatocellular carcinoma. BBA advances 0 42100724
2025 Effects of proximal tubule-specific ATRAP enhancement on hypertension in a remnant kidney chronic kidney disease model of mice. Scientific reports 0 40721451
2025 Lentinan ameliorates angiotensin II-induced hypertension-associated intestinal barrier injury through inactivation of PSMB8-ATRAP signaling. International immunopharmacology 0 40865403
2025 Angiotensin II, miR-34a, and AGTRAP crosstalk in arterial smooth muscle cells. GeroScience 0 41291382

Missed literature

Know a paper Affinage missed for AGTRAP? Flag it for the maintainers and the community.

No submissions yet.